NDAORALTABLET
Approved
May 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Clinical Trials (5)
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
Started Mar 2020
85 enrolled
Diabetes Mellitus, Type 2
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Started Aug 2018
30 enrolled
Healthy
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Started Mar 2018
175 enrolled
Diabetes Mellitus, Type 2
Real World Glycemic Effectiveness of Linagliptin
Started Nov 2017
11,001 enrolled
Diabetes Mellitus, Type 2
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
Started Aug 2017
30 enrolled
Healthy
Loss of Exclusivity
LOE Date
Dec 8, 2037
143 months away
Patent Expiry
Dec 8, 2037
Exclusivity Expiry
Dec 20, 2026
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8883805 | Nov 26, 2025Expired | Product | — |
| 8883805*PED | May 26, 2026 | — | |
| 12178819 | May 4, 2027 | Product | — |
| 11033552 | May 4, 2027 | Product | — |
| 8673927 | May 4, 2027 | U-1503 |